Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12607000178448
Ethics application status
Approved
Date submitted
19/03/2007
Date registered
21/03/2007
Date last updated
21/03/2007
Type of registration
Prospectively registered
Titles & IDs
Public title
Fatty acids, Lipids And Sensory properties of Hazelnuts [The FLASH Study]
Query!
Scientific title
A randomised, controlled dietary intervention to assess the effects of incorporating hazelnuts in three different forms (ground, sliced, whole) into the usual diet, on lipid and lipoprotein mediated risk factors for cardiovascular disease (CVD) in hypercholesterolemic subjects.
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
FLASH
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Subjects with elevated cholesterol level (above 4.8 mmol/L)
1696
0
Query!
Condition category
Condition code
Diet and Nutrition
1788
1788
0
0
Query!
Other diet and nutrition disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The participants will be asked to consume 30g of three different forms (ground, sliced, whole) of hazelnuts each day for twelve weeks. For the first two weeks of the study, the participants will consume their normal diet (Baseline). After this two-week period, they will be randomly allocated to receive one form of the hazelnut for a four-week-period. This will be followed by a two-week washout period where they will not consume any study hazelnut or other nuts. They will then be allocated to receive a second form of hazelnut for four weeks. This again is followed by a two-week washout period. Lastly, they will receive the third form of hazelnut for a period of four weeks. The study lasts 18 weeks in total.
Query!
Intervention code [1]
1655
0
Lifestyle
Query!
Comparator / control treatment
No comparator.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
2502
0
Cholesterol
Query!
Assessment method [1]
2502
0
Query!
Timepoint [1]
2502
0
At 4, 6, 10, 12 and 16 weeks after intervention commencement
Query!
Primary outcome [2]
2503
0
Lipoprotein
Query!
Assessment method [2]
2503
0
Query!
Timepoint [2]
2503
0
At 4, 6, 10, 12 and 16 weeks after intervention commencement
Query!
Secondary outcome [1]
4317
0
Antioxidant capacity
Query!
Assessment method [1]
4317
0
Query!
Timepoint [1]
4317
0
At baseline and at 4, 6, 10, 12 and 16 weeks after intervention commencement.
Query!
Eligibility
Key inclusion criteria
• Healthy • Blood cholesterol > 4.8 mmol/L
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
• People who are taking cholesterol-lowering medication or medication known to affect blood lipid levels• Presence of familial or secondary hyperlipidaemia or major chronic illness• People who have asthma• People who have food allergies • Body Mass Index (BMI) > 30 [weight (kg) / height (m)2].
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participants will be sequentially allocated on basis of entry into study. The six possibilities for sequence for the three treatments will be randomly generated by a researcher who is not involved in the study in any other way.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomised to treatment groups without stratification, using permuted block randomisation.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
26/03/2007
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
48
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
491
0
New Zealand
Query!
State/province [1]
491
0
Query!
Funding & Sponsors
Funding source category [1]
1939
0
Charities/Societies/Foundations
Query!
Name [1]
1939
0
National Heart Foundation of New Zealand
Query!
Address [1]
1939
0
Query!
Country [1]
1939
0
New Zealand
Query!
Primary sponsor type
Individual
Query!
Name
Dr Alex Chisholm
Query!
Address
Query!
Country
Query!
Secondary sponsor category [1]
1750
0
Individual
Query!
Name [1]
1750
0
Dr Rachel Brown
Query!
Address [1]
1750
0
Query!
Country [1]
1750
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
3617
0
University of Otago
Query!
Ethics committee address [1]
3617
0
Query!
Ethics committee country [1]
3617
0
New Zealand
Query!
Date submitted for ethics approval [1]
3617
0
Query!
Approval date [1]
3617
0
29/09/2006
Query!
Ethics approval number [1]
3617
0
06/142
Query!
Summary
Brief summary
Diets high in nuts with favourable fatty acid profiles and other bioactive substances such as phytochemicals can lower plasma cholesterol, and thus reduce the risk of CVD. Epidemiologic studies have consistently demonstrated an inverse association between nut consumption and CVD in different population groups. Numerous clinical studies have shown the cholesterol-lowering effects of several nuts, such as almonds, macademia nuts, peanuts, pecans, walnuts and various nuts. To date, there are only two human intervention trials that have investigated the effect of hazelnut supplementation on plasma cholesterol levels. Furthermore, the physical form in which the nuts are consumed may be important. One study has suggested that the cell walls of intact almond seeds hinder the release of lipid available for digestion, which could lead to a reduction in lipid bio-availability. It is possible that the different forms of nuts may differ in lipid bio-availability and total antioxidant capacity, and thus, have differing effects on lipid and lipoprotein mediated risk factors for CVD. Therefore, the aim of the FLASH study is to investigate the effects of incorporating three different forms (ground, sliced, whole) of hazelnuts into the usual diet on plasma lipids using a randomized, multiple crossover design.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
27758
0
Query!
Address
27758
0
Query!
Country
27758
0
Query!
Phone
27758
0
Query!
Fax
27758
0
Query!
Email
27758
0
Query!
Contact person for public queries
Name
10844
0
Dr Alex Chisholm, Dr Rachel Brown
Query!
Address
10844
0
Department of Human Nutrition
University of Otago
PO Box 56
Dunedin
Query!
Country
10844
0
New Zealand
Query!
Phone
10844
0
+64 3 479 7514, +64 3 479 5839
Query!
Fax
10844
0
+64 3 479 7949
Query!
Email
10844
0
[email protected]
,
[email protected]
Query!
Contact person for scientific queries
Name
1772
0
Dr Alex Chisholm, Dr Rachel Brown
Query!
Address
1772
0
Department of Human Nutrition
University of Otago
PO Box 56
Dunedin
Query!
Country
1772
0
New Zealand
Query!
Phone
1772
0
+64 3 479 7514, +64 3 479 5839
Query!
Fax
1772
0
+64 3 479 7949
Query!
Email
1772
0
[email protected]
,
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF